Opendata, web and dolomites

TETRA TERMINATED

Autologous Stem Cell Seeded Tissue Engineered Trachea

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TETRA project word cloud

Explore the words cloud of the TETRA project. It provides you a very rough idea of what is the project "TETRA" about.

eliminate    maa    organs    risk    autologous    led    quality    prepare    827    tens    dossier    replacements    therapeutic    interventions    pivotal    market    submission    follow    20    synthetic    data    reduce    route    tissues    cell    compassionate    unmet    limitations    disease    seeded    lives    dying    inspire    scaffolds    generate    repeated    accelerated    clinical    48    treating    manufacturing    517    validated    insertion    hospitalised    gmp    22    cells    deaths    11    million    prototype    efficacy    conduct    indication    scaffold    length    subjected    orphan    bowel    airway    liver    competitor    savings    diseases    severe    surviving    patient    susceptible    surgical    sme    tracheal    plan    platform    estimate    trial    atmp    transplants    poorly    infection    structural    commercial    thousands    strategies    standard    patients    rate    limited    tetra    preliminary    care    benefits    life    successful    stent    group    stem   

Project "TETRA" data sheet

The following table provides information about the project.

Coordinator
VIDEREGEN LIMITED 

Organization address
address: INNOVATION CENTRE 1, LIVERPOOL SCIENCE PARK, 131 M ANT
city: LIVERPOOL
postcode: L3 5TF
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.tetra-h2020.eu/
 Total cost 6˙828˙887 €
 EC max contribution 6˙828˙884 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2015-single-stage_RTD
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VIDEREGEN LIMITED UK (LIVERPOOL) coordinator 1˙563˙340.00
2    TMC PHARMA SERVICES LIMITED UK (Hartley Wintney) participant 1˙127˙146.00
3    KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN DE (MUENCHEN) participant 903˙250.00
4    UNIVERSITY COLLEGE LONDON HOSPITALSNHS FOUNDATION TRUST UK (LONDON) participant 669˙578.00
5    NHS BLOOD AND TRANSPLANT UK (WATFORD) participant 535˙250.00
6    MANCHESTER UNIVERSITY NHS FOUNDATION TRUST UK (MANCHESTER) participant 483˙512.00
7    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 455˙118.00
8    INSTYTUT GRUZLICY I CHOROB PLUC PL (WARSZAWA) participant 365˙000.00
9    UNIVERSITA DEGLI STUDI DI BRESCIA IT (BRESCIA) participant 346˙266.00
10    CELL THERAPY CATAPULT LIMITED UK (LONDON) participant 281˙681.00
11    EURAM LIMITED UK (LINCOLN) participant 65˙496.00
12    THE UNIVERSITY OF MANCHESTER UK (MANCHESTER) participant 30˙700.00
13    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 2˙546.00
14    UNIVERSITY HOSPITAL OF SOUTH MANCHESTER NHS FOUNDATION TRUST UK (MANCHESTER) participant 0.00

Map

 Project objective

CLINICAL PROBLEM AND UNMET NEED There are 11,827 patients with severe structural airway disease in Europe. Even with the current standard of care, when hospitalised this group of patients has a 22% risk of dying. Patients are currently subjected to repeated surgical interventions (stent insertion) which have a high failure rate.

Other therapeutic strategies under development include synthetic tracheal scaffolds seeded with patients own stem cells. Preliminary data show that these scaffolds are poorly integrated and are susceptible to infection.

TETRA PROJECT Our SME-led project will address the limitations of standard clinical care and competitor products under development and will: - Build on our successful compassionate use experience using autologous stem cell seeded scaffold-tracheal transplants in 48 patients - Follow on from our Phase I 4 patient INSPIRE clinical trial which will improve on the clinical prototype used in compassionate use cases - Conduct a 48 patient Phase II pivotal clinical trial to provide robust, quality data with validated GMP manufacturing processes to support an accelerated route to market for commercial exploitation in this orphan indication - Prepare a dossier for MAA submission

BENEFITS Our product, an ATMP, aims to eliminate the need for repeated surgical interventions of high risk and limited efficacy, reduce deaths and improve the quality of life for surviving patients. If treating 20% of the patients with severe structural airway disease, we estimate that in Europe our technology will improve the quality and length of patient lives and result in savings of €517 million per year.

We plan to further develop our platform technology to generate other complex tissues/organs such as bowel and liver replacements for clinical applications which will impact the lives of tens of thousands of patient in the EU with bowel and liver diseases.

 Deliverables

List of deliverables.
Project Website Websites, patent fillings, videos etc. 2019-05-31 18:06:05

Take a look to the deliverables list in detail:  detailed list of TETRA deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TETRA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TETRA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More